<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="letter">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203312437436</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203312437436</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Letter to the editor</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Anti-beta2-glycoprotein I antibody and cerebellar ataxia in breast cancer</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Chen</surname><given-names>W-H</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312437436">1</xref>
<xref ref-type="corresp" rid="corresp1-0961203312437436"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Yin</surname><given-names>H-L</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312437436">2</xref>
<xref ref-type="aff" rid="aff1-0961203312437436">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chen</surname><given-names>C-J</given-names></name>
<xref ref-type="aff" rid="aff1-0961203312437436">4</xref>
</contrib>
</contrib-group>
<aff id="aff1-0961203312437436"><sup>1</sup>Department of Neurology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, and College of Medicine, Chang Gung University, Kaohsiung, Taiwan; <sup>2</sup>Department of Clinical Forensic Medicine, Kaohsiung Medical University Hospital, and College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; <sup>3</sup>Institute of Forensic Medicine, Ministry of Justice, Taipei, Taiwan; and <sup>4</sup>Department of Rheumatology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, and College of Medicine, Chang Gung University, Kaohsiung, Taiwan</aff>
<author-notes>
<corresp id="corresp1-0961203312437436">Dr Wei-Hsi Chen, Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, and College of Medicine, Chang Gung University, 123 Tai Pei Road, Niao Sung District, Kaohsiung City, Taiwan Email: <email>brainhemostasis@yahoo.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>21</volume>
<issue>4</issue>
<fpage>460</fpage>
<lpage>462</lpage>
<history>
<date date-type="received"><day>2</day><month>3</month><year>2011</year></date>
<date date-type="accepted"><day>10</day><month>1</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2012. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
</article-meta>
</front>
<body>
<p>Sir,</p>
<p>The family of antiphospholipid antibodies (aPL) is a constellation of autoantibodies reactive to anionic/neutral phospholipids and cofactor proteins, and corresponds to antiphospholipid antibody syndrome (APS). In in vitro studies, aPLs recovered from the serum of APS patients have been found to be able to bind with astrocytes, neurons, ependyma and choroids plexus in the human brain and monkey cerebellum<sup><xref ref-type="bibr" rid="bibr1-0961203312437436">1</xref></sup> and the cortical pyramidal layer and dentate gyrus of the hippocampus in mice in specific regions,<sup><xref ref-type="bibr" rid="bibr2-0961203312437436">2</xref></sup> induce neurotoxicity to cerebellar neurons,<sup><xref ref-type="bibr" rid="bibr3-0961203312437436">3</xref></sup> and modulate neurotransmission. However, aPL-related cerebellar ataxia has rarely been reported in a clinical setting.</p>
<p>We encountered a 61-year-old woman who, within one week, experienced a subacute onset of unsteady gait severe enough to prevent her walking properly and maintaining her daily lifestyle. She denied having any preceding infection, trauma, or medical or familial disease. On presentation, the patient’s vital signs were stable. She was unable to sit or stand properly due to significant tibutation. Abnormal neurological findings included scanning speech, bidirectional horizontal nystagmus, and severe limb and truncal ataxia. The patient was scored as 4 on the modified Rankin scale. Extensive investigations, including head magnetic resonance imaging and angiogram, biochemistry, hematology, serology, immunology, trace elements, lupus study, urinalysis, chest radiography, electrocardiogram, electroencephalogram and cerebrospinal fluid analysis, were normal, with the exception that there was an increase in blood anti-beta2-glycoprotein antibody (aβ2GPI) to 23.5 IU/ml (reference: &lt;10 IU/ml), a prolongation of the activated partial thromboplastin time to 33.7 seconds (reference: &lt;28.9 seconds), and a mild reduction in the platelet count to 115,000/cmm (reference: 150,000–500,000/cmm). Blood lupus anticoagulant (LAC), IgG- and IgM-anticardiolipin antibody (aCL), and antibodies to GM1, GM2, GQ1b, GT1b, GD1a, and GD1b ganglioside were normal. Blood onconeural antibodies, including antibodies to Hu, Yo, Tr, Ri, Tr, CV2, and mGluR1, were not increased. Human leucocyte antigen typing was A2, A7, B35, Cw4, Cw7, DR4, and DQ8. Nerve conduction studies of the facial nerve and peripheral nerves, sympathetic skin response, somatosensory evolved potential and blink reflex were normal. Immunohistochemical analysis did not find staining of beta2-glycoprotein I in the patient’s cancer cells. Accordingly, aβ2GPI-related subacute cerebellar ataxia was interpreted. The patient and her family hesitated to undergo plasmapheresis, pulse therapy or immunosuppressive treatment, and she walked with a crutch at discharge.</p>
<p>During the follow-up period, a fluctuation in the blood aβ2GPI level, ranging from 8.6 to 24.0 IU/ml, was observed. The modified Rankin scale had improved to a score of 3 six months later. About one year after the onset of ataxia, the patient palpated a mass in her right breast that had not been found before. Surgical removal was completed. Microscopic pathology revealed ductal invasive carcinoma. After removal of the breast cancer, the patient’s blood aβ2GPI level had dropped to 4.2 IU/ml at one month and 2.1 IU/ml at three months after the operation, respectively. Since then, she has been able to walk independently without a crutch, and her blood aβ2GPI level, coagulation time, and platelet count have remained within the reference ranges.</p>
<p>Cerebellar ataxia is not very unusual in breast cancer patients. It usually results from paraneoplastic cerebellar degeneration related to onconeural antibodies. Increased aβ2GPI has been reported in breast cancer patients but not in subacute cerebellar ataxia as in our patient before.<sup><xref ref-type="bibr" rid="bibr4-0961203312437436">4</xref></sup> Therefore, we observe an underestimation of non-onconeural antibodies, such as aPL or aβ2GPI, being responsible for immune-mediated cerebellar ataxia in cancer patients.</p>
<p>To date, only in a total of five patients, including ours reported herein, has a concurrence of increased aPL and cerebellar ataxia been reported in the literature after exclusion of cerebellar stroke or other structural lesions.<sup><xref ref-type="bibr" rid="bibr5-0961203312437436">5</xref></sup><sup>–</sup><sup><xref ref-type="bibr" rid="bibr8-0961203312437436">8</xref></sup> These patients included three adults and two children; four patients were female. The responsible aPL were aβ2GPI, aCL−IgM, aCL−IgG, aCL−IgG+IgM+LAC, and aβ2GPI + aCL−IgG+IgM in each patient, respectively. Cancer was identified only in our patient. These findings suggest that any type of APAbs can provoke cerebellar ataxia.</p>
<p>The mechanism of the secondary increase in the blood aβ2GPI level in cancer patients has been fully reviewed.<sup><xref ref-type="bibr" rid="bibr9-0961203312437436">9</xref></sup> In our patient, the core question is whether the increased aβGPI was responsible for the ataxia. aPL are a group of heterogenous autoantibodies, and are able to cross-react with a few autoantigens,<sup><xref ref-type="bibr" rid="bibr9-0961203312437436">9</xref></sup> However, they have not been reported to be able to cross-react with onconeural antigens. A cross-reaction between onconeural antigens and aβ2GPI or aPL is expected to induce cerebellar ataxia similar to onconeural antibodies. We compared the protein sequence of β2GPI with Yo/cdr2 (PCA-1), HuB (Hel-N), HuD, HuC, CV2/CRMP5, Ri (ANNA2), Tr, and mGluR1 antigen. Indeed, we found a variable homology of sequences between β2GPI and these cerebellar ataxia-related onconeural antigens, with the exception of Yo/cdr2 (<xref ref-type="table" rid="table1-0961203312437436">Table 1</xref>). These homologous sequences may indicate cross-reactivity between aβ2GPI/aPL and cerebellar onconeural antigens to a variable magnitude to initiate immune-mediated neurotoxicity similar to onconeural antibodies.
<table-wrap id="table1-0961203312437436" position="float"><label>Table 1</label><caption><p>The protein homology between beta<sub>2</sub>-glycoprotein I and cerebellar ataxia-related onconeural antigens</p></caption>
<graphic alternate-form-of="table1-0961203312437436" xlink:href="10.1177_0961203312437436-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Onconeural antigens</th>
<th colspan="2">Beta<sub>2</sub>-glycoprotein I (β2GPI)</th></tr></thead>
<tbody align="left">
<tr>
<td>Yo antigen (454 aa)</td>
<td/>
<td>No matching</td></tr>
<tr>
<td rowspan="2">Hu-D antigen (380 aa)</td>
<td>β2GPI</td>
<td>21 <bold>R</bold>T<bold>CP</bold>K<bold>P</bold> 26</td></tr>
<tr>
<td>HuD</td>
<td>29 <bold>R</bold>N<bold>CP</bold>S<bold>P</bold> 34</td></tr>
<tr>
<td rowspan="2"/>
<td>β2GPI</td>
<td>288 <bold>NG</bold>MLH<bold>GD</bold>K<bold>V</bold> 296</td></tr>
<tr>
<td>HuD</td>
<td>359 <bold>NG</bold>YRL<bold>GD</bold>R<bold>V</bold> 367</td></tr>
<tr>
<td rowspan="2">HuB antigen (359 aa)</td>
<td>β2GPI</td>
<td>200 <bold>C</bold>RE<bold>V</bold>KCPFPSRPDN<bold>GFVNY</bold> 218</td></tr>
<tr>
<td>HuB</td>
<td>68 <bold>C</bold>KL<bold>V</bold>RDKITGQSLGY<bold>GFVNY</bold> 87</td></tr>
<tr>
<td rowspan="2"/>
<td>β2GPI</td>
<td>90 <bold>L</bold>E<bold>NG</bold>AVRYT<bold>T</bold>FEY<bold>P</bold>N<bold>TI</bold>SFS<bold>C</bold>NT 112</td></tr>
<tr>
<td>HuB</td>
<td>5 <bold>L</bold>S<bold>NG</bold>PTCNN<bold>T</bold>ANG<bold>P</bold>T<bold>TI</bold>NNN<bold>C</bold>SS 27</td></tr>
<tr>
<td rowspan="2"/>
<td>β2GPI</td>
<td>288 <bold>NG</bold>MLH<bold>GD</bold>K<bold>V</bold> 296</td></tr>
<tr>
<td>HuB</td>
<td>338 <bold>NG</bold>YRL<bold>GD</bold>R<bold>V</bold> 346</td></tr>
<tr>
<td rowspan="2"/>
<td>β2GPI</td>
<td>213 <bold>N</bold>GF<bold>VNY</bold>PAKPTLYYKD<bold>K</bold>AT<bold>FG</bold>C 234</td></tr>
<tr>
<td>HuB</td>
<td>40 <bold>N</bold>LI<bold>VNY</bold>LPQNMTQEEL<bold>K</bold>SL<bold>FG</bold>S 61</td></tr>
<tr>
<td rowspan="2">HuC antigen (359 aa)</td>
<td>β2GPI</td>
<td>192 <bold>G</bold>NWTKLPE<bold>C</bold>RE<bold>V</bold>KCPFPS<bold>R</bold>PDN<bold>GFVNYP</bold> 219</td></tr>
<tr>
<td>HuC</td>
<td>60 <bold>G</bold>SIGDIES<bold>C</bold>KL<bold>V</bold>RDKITG<bold>R</bold>DLGY-<bold>GFVNYP</bold> 88</td></tr>
<tr>
<td rowspan="2">CV2 antigen (685 aa)</td>
<td>β2GPI</td>
<td>243 <bold>PE</bold>E<bold>I</bold>ECT<bold>K</bold>L<bold>GN</bold> 253</td></tr>
<tr>
<td>CV2</td>
<td>295 <bold>PE</bold>D<bold>I</bold>KVC<bold>K</bold>F<bold>GN</bold> 305</td></tr>
<tr>
<td rowspan="2"/>
<td>β2GPI</td>
<td>200 <bold>C</bold>REV<bold>KCP</bold>FP<bold>SR</bold> 210</td></tr>
<tr>
<td>CV2</td>
<td>79 <bold>C</bold>KRE<bold>KCP</bold>VL<bold>SR</bold> 89</td></tr>
<tr>
<td rowspan="2"/>
<td>β2GPI</td>
<td>247 <bold>EC</bold>T<bold>KL</bold>GN<bold>W</bold> 254</td></tr>
<tr>
<td>CV2</td>
<td>559 <bold>EC</bold>Q<bold>KL</bold>KS<bold>W</bold> 566</td></tr>
<tr>
<td rowspan="2"/>
<td>β2GPI</td>
<td>115 Y<bold>L</bold>N<bold>G</bold>ADS<bold>AKC</bold>TE<bold>EG</bold>K 129</td></tr>
<tr>
<td>CV2</td>
<td>42 F<bold>L</bold>T<bold>G</bold>S—V<bold>AKC</bold>EN<bold>EG</bold>E 55</td></tr>
<tr>
<td rowspan="2">Ri antigen (510 aa)</td>
<td>β2GPI</td>
<td>295 <bold>K</bold>VSFFC<bold>K</bold>N<bold>K</bold>EKKCSY<bold>TE</bold>DAQC<bold>I</bold>D<bold>GT</bold>I<bold>E</bold> 321</td></tr>
<tr>
<td>Ri</td>
<td>84 <bold>K</bold>L<bold>S</bold>KLS<bold>K</bold>S<bold>K</bold>DFYPGT<bold>TE</bold>RVCL<bold>I</bold>Q<bold>GT</bold>V<bold>E</bold> 110</td></tr>
<tr>
<td rowspan="2"/>
<td>β2GPI</td>
<td>277 <bold>G</bold>E<bold>R</bold>VK<bold>I</bold>QE<bold>K</bold> 285</td></tr>
<tr>
<td>Ri</td>
<td>455 <bold>G</bold>A<bold>R</bold>IQ<bold>I</bold>SK<bold>K</bold> 463</td></tr>
<tr>
<td rowspan="2">Tr antigen (497 aa)</td>
<td>β2GPI</td>
<td>138 <bold>A</bold>P<bold>IIC</bold>PPPSIPTFATLR<bold>V</bold>YK<bold>P</bold>S<bold>AG</bold> 161</td></tr>
<tr>
<td>Tr</td>
<td>423 <bold>A</bold>K<bold>IIC</bold>NTKDNERVVGFH<bold>V</bold>LG<bold>P</bold>N<bold>AG</bold> 446</td></tr>
<tr>
<td rowspan="2"/>
<td>β2GPI</td>
<td>29 <bold>L</bold>P<bold>F</bold>S<bold>T</bold>VV<bold>PL</bold>K<bold>T</bold>FYEP<bold>G</bold> 44</td></tr>
<tr>
<td>Tr</td>
<td>41 <bold>L</bold>D<bold>F</bold>G<bold>T</bold>PT<bold>PL</bold>G<bold>T</bold>RWGL<bold>G</bold> 56</td></tr>
<tr>
<td rowspan="2">mGluR1 antigen (1,194 aa)</td>
<td>β2GPI</td>
<td>3 S<bold>PV</bold>LILF<bold>S</bold>SF<bold>LC</bold>HVAI<bold>AG</bold> 20</td></tr>
<tr>
<td>mGluR1</td>
<td>620 T<bold>PV</bold>VKSS<bold>S</bold>RE<bold>LC</bold>YIIL<bold>AG</bold> 637</td></tr>
<tr>
<td rowspan="2"/>
<td>β2GPI</td>
<td>141 I<bold>C</bold>P<bold>PP</bold>SIPTF<bold>A</bold>T–<bold>LR</bold>V<bold>YK</bold>P<bold>S</bold>A 160</td></tr>
<tr>
<td>mGluR1</td>
<td>1171 L<bold>C</bold>T<bold>PP</bold>NV-SY<bold>A</bold>SVI<bold>LR</bold>D<bold>YK</bold>Q<bold>S</bold>S 1191</td></tr>
<tr>
<td rowspan="2"/>
<td>β2GPI</td>
<td>319 <bold>T</bold>IE<bold>VP</bold>KC<bold>F</bold>K<bold>E</bold>HSSL<bold>AF</bold> 334</td></tr>
<tr>
<td>mGluR1</td>
<td>774 <bold>T</bold>RN<bold>VP</bold>AN<bold>F</bold>N<bold>E</bold>AKYI<bold>AF</bold> 789</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203312437436"><p>Similar homology sequences are evaluated by BLAST and are marked in bold.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Distinct onconeural antibodies elicit neurological deficits to different magnitudes. The anti-Hu antibody causes cerebellar ataxia more frequently than other onconeural antibodies. In paraneoplastic cerebellar degeneration, nystagmus was present in 33%, 68%, 69%, and 86% and dysarthria in 0%, 84%, 50%, and 86% of patients with increased anti-Ri, anti-Yo, anti-Hu, and anti-Tr antibody, respectively.<sup><xref ref-type="bibr" rid="bibr10-0961203312437436">10</xref></sup> As the relationship between increased aβ2GPI/aPL and paraneoplastic cerebellar degeneration is unknown, we are unable to compare aβ2GPI/aPL with onconeural antibodies owing to limited data. In our patient, scanning speech and nystagmus were found, which may suggest that aβ2GPI interacts with cerebellar Purkinje cells differently from the anti-Ri antibody.</p>
<p>The findings in our patient alert us to three issues. First, aβ2GPI or aPL should be screened in cases of nonhereditary cerebellar ataxia, even without the typical manifestation of aPL or other immunological disease, until the underlying cause is known. Second, an elevation of the blood aβ2GPI or aPL level in association with pancerebellar ataxia should alert physicians to an occult malignancy until a corresponding lesion is identified. Third, aβ2GPI can cause isolated neurological deficit without the typical feature of APS.</p>
</body>
<back>
<sec id="sec1-0961203312437436"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p></sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203312437436"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caronti</surname><given-names>B</given-names></name><name><surname>Calderaro</surname><given-names>C</given-names></name><name><surname>Alessandri</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells</article-title>. <source>J Autoimmun</source> <year>1998</year>; <volume>11</volume>: <fpage>425</fpage>–<lpage>429</lpage>.</citation></ref>
<ref id="bibr2-0961203312437436"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shoenfeld</surname><given-names>Y</given-names></name><name><surname>Nahum</surname><given-names>A</given-names></name><name><surname>Korczyn</surname><given-names>AD</given-names></name><etal/></person-group>. <article-title>Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer</article-title>. <source>Lupus</source> <year>2003</year>; <volume>12</volume>: <fpage>436</fpage>–<lpage>442</lpage>.</citation></ref>
<ref id="bibr3-0961203312437436"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Riccio</surname><given-names>A</given-names></name><name><surname>Andreassi</surname><given-names>C</given-names></name><name><surname>Eboli</surname><given-names>ML</given-names></name></person-group>. <article-title>Antiphospholipid antibodies bind to rat cerebellar granule cells: the role of N-methyl-D-aspartate receptors</article-title>. <source>Neurosci Lett</source> <year>1998</year>; <volume>257</volume>: <fpage>116</fpage>–<lpage>118</lpage>.</citation></ref>
<ref id="bibr4-0961203312437436"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asherson</surname><given-names>RA</given-names></name><name><surname>D'Cruz</surname><given-names>D</given-names></name></person-group>. <article-title>Vascular occlusions in a patient with low positive antiphospholipid antibodies and subsequent development of breast carcinoma: a diagnostic dilemma</article-title>. <source>Clin Rheumatol</source> <year>2007</year>; <volume>26</volume>: <fpage>1531</fpage>–<lpage>1533</lpage>.</citation></ref>
<ref id="bibr5-0961203312437436"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frohman</surname><given-names>L</given-names></name><name><surname>Turbin</surname><given-names>R</given-names></name><name><surname>Bielory</surname><given-names>L</given-names></name><name><surname>Wolansky</surname><given-names>L</given-names></name><name><surname>Lambert</surname><given-names>WC</given-names></name><name><surname>Cook</surname><given-names>S</given-names></name></person-group>. <article-title>Autoimmune optic neuropathy with anticardiolipin antibody mimicking multiple sclerosis in a child</article-title>. <source>Am J Ophthalmol</source> <year>2003</year>; <volume>136</volume>: <fpage>358</fpage>–<lpage>360</lpage>.</citation></ref>
<ref id="bibr6-0961203312437436"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>WH</given-names></name><name><surname>Chen</surname><given-names>CJ</given-names></name></person-group>. <article-title>Antiphospholipid antibody, head-shaking and ataxia: an evidence of non-vascular neurotoxicity and successful treatment by plasmapheresis</article-title>. <source>Rheumatol Int</source> <year>2009</year>; <volume>29</volume>: <fpage>827</fpage>–<lpage>829</lpage>.</citation></ref>
<ref id="bibr7-0961203312437436"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishikawa</surname><given-names>N</given-names></name><name><surname>Kobayashi</surname><given-names>M</given-names></name></person-group>. <article-title>Recurrent acute cerebellar ataxia associated with anti-cardiolipin antibodies</article-title>. <source>Brain Dev</source> <year>2010</year>; <volume>32</volume>: <fpage>588</fpage>–<lpage>591</lpage>.</citation></ref>
<ref id="bibr8-0961203312437436"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>JH</given-names></name></person-group>. <article-title>Dementia, ataxia and parkinsonism associated with the antiphospholipid syndrome</article-title>. <source>Parkinsonism Relat Disord</source> <year>2011</year>; <volume>17</volume>: <fpage>215</fpage>–<lpage>216</lpage>.</citation></ref>
<ref id="bibr9-0961203312437436"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tincani</surname><given-names>A</given-names></name><name><surname>Taraborelli</surname><given-names>M</given-names></name><name><surname>Cattaneo</surname><given-names>R</given-names></name></person-group>. <article-title>Antiphospholipid antibodies and malignancies</article-title>. <source>Autoimmun Rev</source> <year>2010</year>; <volume>9</volume>: <fpage>200</fpage>–<lpage>202</lpage>.</citation></ref>
<ref id="bibr10-0961203312437436"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shams'ili</surname><given-names>S</given-names></name><name><surname>Grefkens</surname><given-names>J</given-names></name><name><surname>de Leeuw</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients</article-title>. <source>Brain</source> <year>2003</year>; <volume>126</volume>: <fpage>1409</fpage>–<lpage>1418</lpage>.</citation></ref>
</ref-list>
<sec id="sec2-0961203312437436"><title/>
<p>W-H Chen<sup>1</sup>, H-L Yin<sup>2,3</sup> and C-J Chen<sup>4</sup></p>
<p><sup>1</sup>Department of Neurology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, and College of Medicine, Chang Gung University, Kaohsiung, Taiwan; <sup>2</sup>Department of Clinical Forensic Medicine, Kaohsiung Medical University Hospital, and College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; <sup>3</sup>Institute of Forensic Medicine, Ministry of Justice, Taipei, Taiwan; and <sup>4</sup>Department of Rheumatology, Chang Gung Memorial Hospital-Kaohsiung Medical Center, and College of Medicine, Chang Gung University, Kaohsiung, Taiwan</p></sec>
</back>
</article>